Based on these previous findings, we re-develop HER2DX risk score based on 4 gene expression-based signatures tracking adaptive immune cell infiltration, tumour cell proliferation, HER2 amplicon expression and tumour cell luminal differentiation, together with tumour stage (T1 vs. T2 vs. T3-4) and nodal stage (N0 vs. N1 vs. N2-3). Here, ERBB2 is linked to neoplasm.